Compare Amphastar Pharmaceuticals Inc (AMPH) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Remitly Global Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Remitly Global Inc trades at $23.62 (market cap $5.01B). The key difference: Remitly Global Inc is far larger — about 6.1× Amphastar Pharmaceuticals Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | RELY | |
|---|---|---|
Market Cap | $826.08M | $5.01B |
Sector | Health | Technology |
52-Week High | $30.81 | $24.28 |
52-Week Low | $16.87 | $12.20 |
Enterprise Value | $1.22B | $4.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
RELY trades at $23.77, up 0.89% today, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q1 2026 EPS of $0.23, beating expectations, and raised full-year guidance to $1.96–$1.975 billion revenue. Recent news highlights a UAE license and market share gains.
Outlook is positive with 92% analyst buy ratings and a $26.75 consensus target, but high P/E of 49.52 and competitive pressures in remittance pose risks. Profitability has turned positive, with net income reaching $67.93M in 2025 after prior losses, signaling a sustainable growth trajectory if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
